AX-0810 program targeting NTCP for cholestatic diseases and AX-1412 program targeting B4GALT1 for cardiovascular diseases advancing to the clinic in late 2024/early 2025 with translational data and trial design details to be announced in H2 2024$4.5 million in milestones
… ProQR Announces Proposed Underwritten Public Offering of … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through … (the “Offering”). All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a …
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that it intends to offer
… ProQR Announces Proposed Underwritten Public Offering of … and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a …
… ProQR Announces Proposed Underwritten Public Offering of … and CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters …
… ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory … a key strategic role in the development and advancement of ProQR’s growing ophthalmology pipeline. LEIDEN, The … chaired by Gerard Platenburg, Chief Innovation Officer of ProQR, now consists of six members including: Drs. Art Levin, …
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagemen
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
… ProQR Announces Third Quarter 2024 Operating and Financial … & CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company … approximately $82.1 million. Research and development (R&D) costs were €9.4 million for the quarter ended September …